Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Dec;83(12):1688–1695. doi: 10.1054/bjoc.2000.1522

C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance

S L Deming 1, S J Nass 2, R B Dickson 1, B J Trock 1
PMCID: PMC2363455  PMID: 11104567

Abstract

Data from basic research suggests that amplification of the proto-oncogene c-myc is important in breast cancer pathogenesis, but its frequency of amplification and prognostic relevance in human studies have been inconsistent. In an effort to clarify the clinical significance of c-myc amplification in breast cancer, we conducted a comprehensive literature search and a meta-analysis in which 29 studies were evaluated. The weighted average frequency of c-myc amplification in breast tumours was 15.7% (95% CI = 12.5–18.8%), although estimates in individual studies exhibited significant heterogeneity, P< 0.0001. C-myc amplification exhibited significant but weak associations with tumour grade (RR = 1.61), lymph-node metastasis (RR = 1.24), negative progesterone receptor status (RR = 1.27), and postmenopausal status (RR = 0.82). Amplification was significantly associated with risk of relapse and death, with pooled estimates RR = 2.05 (95% CI = 1.51–2.78) and RR = 1.74 (95% CI = 1.27–2.39), respectively. This effect did not appear to be merely a surrogate for other prognostic factors. These results suggest that c-myc amplification is relatively common in breast cancer and may provide independent prognostic information. More rigorous studies with consistent methodology are required to validate this association, and to investigate its potential as a molecular predictor of specific therapy response. © 2000 Cancer Research Campaign http://www.bjcancer.com

Keywords: c-myc, amplification, breast cancer, prognostic markers, meta-analysis

Full Text

The Full Text of this article is available as a PDF (120.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adnane J., Gaudray P., Simon M. P., Simony-Lafontaine J., Jeanteur P., Theillet C. Proto-oncogene amplification and human breast tumor phenotype. Oncogene. 1989 Nov;4(11):1389–1395. [PubMed] [Google Scholar]
  2. Alitalo K., Schwab M., Lin C. C., Varmus H. E., Bishop J. M. Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma. Proc Natl Acad Sci U S A. 1983 Mar;80(6):1707–1711. doi: 10.1073/pnas.80.6.1707. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Berns E. M., Klijn J. G., van Putten W. L., van Staveren I. L., Portengen H., Foekens J. A. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res. 1992 Mar 1;52(5):1107–1113. [PubMed] [Google Scholar]
  4. Berns E. M., Klijn J. G., van Staveren I. L., Portengen H., Noordegraaf E., Foekens J. A. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. Eur J Cancer. 1992;28(2-3):697–700. doi: 10.1016/s0959-8049(05)80129-7. [DOI] [PubMed] [Google Scholar]
  5. Bièche I., Champème M. H., Lidereau R. A tumor suppressor gene on chromosome 1p32-pter controls the amplification of MYC family genes in breast cancer. Cancer Res. 1994 Aug 15;54(16):4274–4276. [PubMed] [Google Scholar]
  6. Bonilla M., Ramirez M., Lopez-Cueto J., Gariglio P. In vivo amplification and rearrangement of c-myc oncogene in human breast tumors. J Natl Cancer Inst. 1988 Jul 6;80(9):665–671. doi: 10.1093/jnci/80.9.665. [DOI] [PubMed] [Google Scholar]
  7. Borg A., Baldetorp B., Fernö M., Olsson H., Sigurdsson H. c-myc amplification is an independent prognostic factor in postmenopausal breast cancer. Int J Cancer. 1992 Jul 9;51(5):687–691. doi: 10.1002/ijc.2910510504. [DOI] [PubMed] [Google Scholar]
  8. Brouillet J. P., Theillet C., Maudelonde T., Defrenne A., Simony-Lafontaine J., Sertour J., Pujol H., Jeanteur P., Rochefort H. Cathepsin D assay in primary breast cancer and lymph nodes: relationship with c-myc, c-erb-B-2 and int-2 oncogene amplification and node invasiveness. Eur J Cancer. 1990 Apr;26(4):437–441. doi: 10.1016/0277-5379(90)90012-i. [DOI] [PubMed] [Google Scholar]
  9. Champème M. H., Bièche I., Hacène K., Lidereau R. Oncogene amplification per se: an independent prognostic factor in human breast cancer. Mol Carcinog. 1994 Dec;11(4):189–191. doi: 10.1002/mc.2940110403. [DOI] [PubMed] [Google Scholar]
  10. Cline M. J., Battifora H., Yokota J. Proto-oncogene abnormalities in human breast cancer: correlations with anatomic features and clinical course of disease. J Clin Oncol. 1987 Jul;5(7):999–1006. doi: 10.1200/JCO.1987.5.7.999. [DOI] [PubMed] [Google Scholar]
  11. Contegiacomo A., Pizzi C., De Marchis L., Alimandi M., Delrio P., Di Palma E., Petrella G., Ottini L., French D., Frati L. High cell kinetics is associated with amplification of the int-2, bcl-1, myc and erbB-2 proto-oncogenes and loss of heterozygosity at the DF3 locus in primary breast cancers. Int J Cancer. 1995 Mar 29;61(1):1–6. doi: 10.1002/ijc.2910610102. [DOI] [PubMed] [Google Scholar]
  12. Courjal F., Cuny M., Simony-Lafontaine J., Louason G., Speiser P., Zeillinger R., Rodriguez C., Theillet C. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res. 1997 Oct 1;57(19):4360–4367. [PubMed] [Google Scholar]
  13. Dalla-Favera R., Wong-Staal F., Gallo R. C. Onc gene amplification in promyelocytic leukaemia cell line HL-60 and primary leukaemic cells of the same patient. Nature. 1982 Sep 2;299(5878):61–63. doi: 10.1038/299061a0. [DOI] [PubMed] [Google Scholar]
  14. Dang C. V. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol. 1999 Jan;19(1):1–11. doi: 10.1128/mcb.19.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Dickersin K., Berlin J. A. Meta-analysis: state-of-the-science. Epidemiol Rev. 1992;14:154–176. doi: 10.1093/oxfordjournals.epirev.a036084. [DOI] [PubMed] [Google Scholar]
  16. Edwards P. A., Ward J. L., Bradbury J. M. Alteration of morphogenesis by the v-myc oncogene in transplants of mammary gland. Oncogene. 1988 Apr;2(4):407–412. [PubMed] [Google Scholar]
  17. Escot C., Theillet C., Lidereau R., Spyratos F., Champeme M. H., Gest J., Callahan R. Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci U S A. 1986 Jul;83(13):4834–4838. doi: 10.1073/pnas.83.13.4834. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Garcia I., Dietrich P. Y., Aapro M., Vauthier G., Vadas L., Engel E. Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. Cancer Res. 1989 Dec 1;49(23):6675–6679. [PubMed] [Google Scholar]
  19. George S. L., Desu M. M. Planning the size and duration of a clinical trial studying the time to some critical event. J Chronic Dis. 1974 Feb;27(1):15–24. doi: 10.1016/0021-9681(74)90004-6. [DOI] [PubMed] [Google Scholar]
  20. Guérin M., Barrois M., Terrier M. J., Spielmann M., Riou G. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene Res. 1988;3(1):21–31. [PubMed] [Google Scholar]
  21. Harada Y., Katagiri T., Ito I., Akiyama F., Sakamoto G., Kasumi F., Nakamura Y., Emi M. Genetic studies of 457 breast cancers. Clinicopathologic parameters compared with genetic alterations. Cancer. 1994 Oct 15;74(8):2281–2286. doi: 10.1002/1097-0142(19941015)74:8<2281::aid-cncr2820740812>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  22. Hayes D. F., Trock B., Harris A. L. Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? Breast Cancer Res Treat. 1998;52(1-3):305–319. doi: 10.1023/a:1006197805041. [DOI] [PubMed] [Google Scholar]
  23. Janocko L. E., Lucke J. F., Groft D. W., Brown K. A., Smith C. A., Pollice A. A., Singh S. G., Yakulis R., Hartsock R. J., Shackney S. E. Assessing sequential oncogene amplification in human breast cancer. Cytometry. 1995 Sep 1;21(1):18–22. doi: 10.1002/cyto.990210106. [DOI] [PubMed] [Google Scholar]
  24. Jenkins R. B., Qian J., Lieber M. M., Bostwick D. G. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res. 1997 Feb 1;57(3):524–531. [PubMed] [Google Scholar]
  25. Kreipe H., Feist H., Fischer L., Felgner J., Heidorn K., Mettler L., Parwaresch R. Amplification of c-myc but not of c-erbB-2 is associated with high proliferative capacity in breast cancer. Cancer Res. 1993 Apr 15;53(8):1956–1961. [PubMed] [Google Scholar]
  26. Leder A., Pattengale P. K., Kuo A., Stewart T. A., Leder P. Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development. Cell. 1986 May 23;45(4):485–495. doi: 10.1016/0092-8674(86)90280-1. [DOI] [PubMed] [Google Scholar]
  27. Little C. D., Nau M. M., Carney D. N., Gazdar A. F., Minna J. D. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature. 1983 Nov 10;306(5939):194–196. doi: 10.1038/306194a0. [DOI] [PubMed] [Google Scholar]
  28. Lönn U., Lönn S., Nilsson B., Stenkvist B. Prognostic value of erb-B2 and myc amplification in breast cancer imprints. Cancer. 1995 Jun 1;75(11):2681–2687. doi: 10.1002/1097-0142(19950601)75:11<2681::aid-cncr2820751107>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  29. Mertens F., Johansson B., Höglund M., Mitelman F. Chromosomal imbalance maps of malignant solid tumors: a cytogenetic survey of 3185 neoplasms. Cancer Res. 1997 Jul 1;57(13):2765–2780. [PubMed] [Google Scholar]
  30. Meyers S. L., O'Brien M. T., Smith T., Dudley J. P. Analysis of the int-1, int-2, c-myc, and neu oncogenes in human breast carcinomas. Cancer Res. 1990 Sep 15;50(18):5911–5918. [PubMed] [Google Scholar]
  31. Münzel P., Marx D., Köchel H., Schauer A., Bock K. W. Genomic alterations of the c-myc protooncogene in relation to the overexpression of c-erbB2 and Ki-67 in human breast and cervix carcinomas. J Cancer Res Clin Oncol. 1991;117(6):603–607. doi: 10.1007/BF01613296. [DOI] [PubMed] [Google Scholar]
  32. Nagayama K., Watatani M. Analysis of genetic alterations related to the development and progression of breast carcinoma. Jpn J Cancer Res. 1993 Nov;84(11):1159–1164. doi: 10.1111/j.1349-7006.1993.tb02816.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Nass S. J., Dickson R. B. Defining a role for c-Myc in breast tumorigenesis. Breast Cancer Res Treat. 1997 May;44(1):1–22. doi: 10.1023/a:1005858611585. [DOI] [PubMed] [Google Scholar]
  34. Ottestad L., Andersen T. I., Nesland J. M., Skrede M., Tveit K. M., Nustad K., Børresen A. L. Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis. Acta Oncol. 1993;32(3):289–294. doi: 10.3109/02841869309093597. [DOI] [PubMed] [Google Scholar]
  35. Prados J., Melguizo C., Fernández A., Aránega A. E., Alvarez L., Aránega A. Inverse expression of mdr 1 and c-myc genes in a rhabdomyosarcoma cell line resistant to actinomycin d. J Pathol. 1996 Sep;180(1):85–89. doi: 10.1002/(SICI)1096-9896(199609)180:1<85::AID-PATH626>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]
  36. Riva-Lavieille C. Chimiorésistance, oncogènes et anti-oncogènes dans les tumeurs épithéliales. Bull Cancer. 1994 Dec;81 (Suppl 2):105s–111s. [PubMed] [Google Scholar]
  37. Roux-Dosseto M., Romain S., Dussault N., Desideri C., Piana L., Bonnier P., Tubiana N., Martin P. M. c-myc gene amplification in selected node-negative breast cancer patients correlates with high rate of early relapse. Eur J Cancer. 1992;28A(10):1600–1604. doi: 10.1016/0959-8049(92)90050-c. [DOI] [PubMed] [Google Scholar]
  38. Scorilas A., Yotis J., Gouriotis D., Keramopoulos A., Ampela K., Trangas T., Talieri M. Cathepsin-D and c-erb-B 2 have an additive prognostic value for breast cancer patients. Anticancer Res. 1993 Sep-Oct;13(5C):1895–1900. [PubMed] [Google Scholar]
  39. Scorilas A., Yotis J., Stravolemos K., Gouriotis D., Keramopoulos A., Ampela K., Talieri M., Trangas T. c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients. Anticancer Res. 1995 Jul-Aug;15(4):1543–1547. [PubMed] [Google Scholar]
  40. Sierra A., Castellsague X., Escobedo A., Moreno A., Drudis T., Fabra A. Synergistic cooperation between c-Myc and Bcl-2 in lymph node progression of T1 human breast carcinomas. Breast Cancer Res Treat. 1999 Mar;54(1):39–45. doi: 10.1023/a:1006120006471. [DOI] [PubMed] [Google Scholar]
  41. Soengas M. S., Alarcón R. M., Yoshida H., Giaccia A. J., Hakem R., Mak T. W., Lowe S. W. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science. 1999 Apr 2;284(5411):156–159. doi: 10.1126/science.284.5411.156. [DOI] [PubMed] [Google Scholar]
  42. Tavassoli M., Quirke P., Farzaneh F., Lock N. J., Mayne L. V., Kirkham N. c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma. Br J Cancer. 1989 Oct;60(4):505–510. doi: 10.1038/bjc.1989.303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Trock B. J., Leonessa F., Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst. 1997 Jul 2;89(13):917–931. doi: 10.1093/jnci/89.13.917. [DOI] [PubMed] [Google Scholar]
  44. Tsuda H., Hirohashi S., Shimosato Y., Hirota T., Tsugane S., Yamamoto H., Miyajima N., Toyoshima K., Yamamoto T., Yokota J. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res. 1989 Jun 1;49(11):3104–3108. [PubMed] [Google Scholar]
  45. Varley J. M., Swallow J. E., Brammar W. J., Whittaker J. L., Walker R. A. Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene. 1987;1(4):423–430. [PubMed] [Google Scholar]
  46. Varmus H. E. The molecular genetics of cellular oncogenes. Annu Rev Genet. 1984;18:553–612. doi: 10.1146/annurev.ge.18.120184.003005. [DOI] [PubMed] [Google Scholar]
  47. Walker T. L., White J. D., Esdale W. J., Burton M. A., DeCruz E. E. Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression. Br J Cancer. 1996 Mar;73(5):610–614. doi: 10.1038/bjc.1996.105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Yamashita H., Kobayashi S., Iwase H., Itoh Y., Kuzushima T., Iwata H., Itoh K., Naito A., Yamashita T., Masaoka A. Analysis of oncogenes and tumor suppressor genes in human breast cancer. Jpn J Cancer Res. 1993 Aug;84(8):871–878. doi: 10.1111/j.1349-7006.1993.tb02060.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Zhou D. J., Ahuja H., Cline M. J. Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease. Oncogene. 1989 Jan;4(1):105–108. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES